Addex Rises on Positive Rodent Experiment Results: Zurich Mover

Addex Therapeutics Ltd. (ADXN), a Swiss biotechnology company, rose to the highest level in two weeks after saying an experimental molecule influenced growth-hormone concentrations in rodents.

Addex advanced as much as 3.8 percent to 6.80 Swiss francs in Zurich, the highest price since May 7, and was up 3.1 percent at 12:14 p.m. local time, giving the Geneva-based company a market value of 60.5 million Swiss francs ($62.4 million).

Results show that the ADX71441 molecule, depending on its dosage, leads to changes in the concentration of growth hormones, the Geneva-based company said in a statement. The development could provide “an understanding of the therapeutic potential of ADX71441,” Chief Scientific Officer Graham Dixon said in the statement.

Growth-hormone concentrations have been demonstrated to have an effect on anxiety, pain, overactive bladder and alcohol addiction in pre-clinical models, Addex said.

To contact the reporter on this story: Carolyn Bandel in Zurich at cbandel@bloomberg.net

To contact the editor responsible for this story: Frank Connelly at fconnelly@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.